Study of the Metabolism of Danicopan in Healthy Adults

Study Identifier:
ALXN2040-HV-119
ClinicalTrials.gov Identifier:
NCT04609696
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: Danicopan: Powder-In-Capsule 1
  • Drug: Danicopan: Powder-In-Capsule 2
  • Drug: Danicopan: Tablet
Date
Oct 2020 - Dec 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: Danicopan: Powder-In-Capsule 1
  • Drug: Danicopan: Powder-In-Capsule 2
  • Drug: Danicopan: Tablet
Date
Oct 2020 - Dec 2020
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This is a 2-part open-label, randomized, single-dose, 3-sequence, 3-period crossover, relative bioavailability, and food-effect study comparing different formulations of danicopan in healthy adult participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
Tempe, Arizona, United States, 85283
Status
N/A